Company / Revenue
Bristol Myers Squibb Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$48.2B
FY2025
5-year range
$26.1B / $48.3B
FY2021-FY2025
Trend
-0.2%
vs FY2024
Sector context
#6 of 155
Health Care
What the data says
Among 155 Health Care companies, Bristol Myers Squibb is in the top 4% for revenue. Revenue has fluctuated over the past 10 years, ranging from $15.9B in FY2016 to $48.3B in FY2024.
Based on SEC 10-K filings.
$48.2B in FY2025 with a 5-year CAGR of +2.5%. Top quartile in the Health Care sector.
Improved from $46.4B to $48.2B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +4.3%
- 5-Year CAGR
- +2.5%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 155This company $48.2B Sector average $4.5B
▼
+978.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.5%, indicating consistent growth.
- In FY2025, revenue decreased 0.2% year-over-year.
- Ranks #6 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.2B | -0.2% |
| FY2024 | $48.3B | +4.1% |
| FY2023 | $46.4B | +9.1% |
| FY2022 | $42.5B | +62.6% |
| FY2021 | $26.1B | -38.5% |
| FY2020 | $42.5B | +104.6% |
| FY2019 | $20.8B | +6.9% |
| FY2018 | $19.4B | -6.5% |
| FY2017 | $20.8B | +30.8% |
| FY2016 | $15.9B | -3.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026